First patient dosed in Phase 3 EMPEROR study of zorevunersen for Dravet syndrome by Stoke and Biogen

Stoke Therapeutics, Inc.

First patient dosed in global Phase 3 EMPEROR study of zorevunersen for Dravet syndrome.
Randomized 1:1 vs sham over 52 weeks; primary endpoint: change in major motor seizure frequency at Week 28.
Zorevunersen is an investigational antisense oligonucleotide; potential first disease-modifying treatment for Dravet syndrome.
Key secondary endpoints include cognition/behavior via Vineland-3 subdomains at Week 52.
Enrollment: ages 2-18 with SCN1A mutation; open-label extension offered to eligible participants.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.